Biogen (BIIB) Total Current Liabilities (2009 - 2026)
Biogen (BIIB) posted quarterly Total Current Liabilities of $3.9 billion for Q2 2026, up 23.04% year-over-year from $3.2 billion in Q2 2025, and up 30.62% quarter-over-quarter from $3.0 billion in Q1 2026.
Biogen (BIIB) Total Current Liabilities (2009 - 2026) Analysis & Trends
Biogen's Total Current Liabilities history runs 18 years deep, the most recent figure standing at $3.9 billion for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 23.04% year-over-year to $3.9 billion; the TTM figure through Jun 2026 stood at $3.9 billion (up 23.04% YoY), while the FY2025 annual figure was $3.3 billion, down 39.42% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $3.9 billion, up from $3.0 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $5.5 billion in Q4 2024, with the low at $3.0 billion in Q1 2026.
- The 5-year median for Total Current Liabilities is $3.4 billion (2023), against an average of $3.9 billion.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities soared 64.37% in 2025, then slumped 43.39% in 2026.
- Biogen's Total Current Liabilities stood at $3.3 billion in 2022, then grew by 4.93% to $3.4 billion in 2023, then soared by 60.99% to $5.5 billion in 2024, then sank by 39.42% to $3.3 billion in 2025, then rose by 16.95% to $3.9 billion in 2026.
- Business Quant data shows BIIB's Total Current Liabilities at $3.9 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 3.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92 Bn |
| Mar 31, 2026 | 3.00 Bn |
| Dec 31, 2025 | 3.35 Bn |
| Sep 30, 2025 | 3.29 Bn |
| Jun 30, 2025 | 3.18 Bn |
| Mar 31, 2025 | 5.30 Bn |
| Dec 31, 2024 | 5.53 Bn |
| Sep 30, 2024 | 5.43 Bn |
| Jun 30, 2024 | 3.11 Bn |
| Mar 31, 2024 | 3.22 Bn |
| Dec 31, 2023 | 3.43 Bn |
| Sep 30, 2023 | 5.02 Bn |
| Jun 30, 2023 | 3.19 Bn |
| Mar 31, 2023 | 3.01 Bn |
| Dec 31, 2022 | 3.27 Bn |
| Sep 30, 2022 | 3.93 Bn |
| Jun 30, 2022 | 5.02 Bn |
| Mar 31, 2022 | 3.95 Bn |
| Dec 31, 2021 | 4.30 Bn |
| Sep 30, 2021 | 4.21 Bn |